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A 38-year-old Caucasian gravida 2 para 1 at 34 weeks gestation pre-
sented to the gynecologic oncologist for consideration of a risk-reducing
hysterectomy and BSO as soon as possible after delivery, due to Lynch
syndrome and an antepartum diagnosis of a MSH6 deleterious
mutation. The patient's family history was notable for three aunts
with endometrial cancer and an aunt with ovarian and endometrial
cancers. Her mother and three other family members had known
MSH6 deleterious mutations. There was no known history of colon
or other extracolonic cancers.
The patient's obstetrical history included one prior term spontane-1. Introduction
Lynch syndrome is themost common cause of hereditary endometrial
cancer and the second most common cause of hereditary ovarian cancer
(Crispens, 2012; Meyer et al., 2009; Lachiewicz et al., 2014). Prophylactic
hysterectomy and bilateral salpingo-oophorectomy (BSO) should be
discussed with patients as a risk-reducing option for endometrial and
ovarian cancers at the completion of childbearing (Lancaster et al.,
2015; Committee on Practice B-G, Society of Gynecologic O, 2014).
However, the precise timing of prophylactic hysterectomy and BSO, in-
cluding within the postpartum period is not well deﬁned.
Here, we report a case of a woman with Lynch syndrome who
underwent prophylactic hysterectomy and BSO approximately
15 weeks postpartum. Her course was notable for persistent post-
partum bleeding and intraoperative hemorrhage at the time of hys-
terectomy. Final pathology revealed an incidental placenta increta
and focal endometrial hyperplasia with atypia.s and Gynecology, Division of
Center, 1161 21st Ave South,
bele).
. This is an open access article underous vaginal delivery and her gynecologic history was notable for poly-
cystic ovarian disease and secondary infertility. Her second pregnancy
was conceived with letrazole. Her prenatal course was uncomplicated.
Due to advanced maternal age, she had serial ultrasounds that were
normal and showed a normal fundal placenta. The patient delivered a
female infant at term at an outside hospital. The vaginal delivery was
uncomplicated with normal delivery of an intact placenta, per report.
In the antepartum period, the patient was counseled about the need
for additional workup postpartum to exclude occult malignancy. She
was also counseled extensively about the potential for increased risk
of complications from a hysterectomy performed close to delivery.
At 10 weeks postpartum, the patient was evaluated with the complaint
of persistent postpartum bleeding. On examination, she had an 8 week
size uterus with no palpable adnexal masses. Transvaginal ultrasound
showed an echogenic nodular mass within the endometrial cavity con-
sistentwith avascular retained products of conception or an endometri-
al polyp. A serum CA-125 was 8.3 U/ml and the patient's urine hCG test
was negative. The patient underwent a hysteroscopy, dilation and cu-
rettage (D&C) andwas found to have irregular polypoid tissue in the en-
dometrial cavity. Pathology revealed chorionic villi consistent with
retained products of conception and no evidence of hyperplasia or ma-
lignancy. Screening colonoscopy revealed a tubular adenoma.
Approximately 15weeks postpartum, the patient underwent amin-
imally invasive hysterectomy and BSO. Brisk bleeding from the lower
uterine segment and cervix upon placement of the uterine manipulator
was controlled with pressure and hemostatic sutures. The remainder of
the case was uneventful and the total estimated blood loss for the
procedure was 300 ml. Frozen section was negative for malignancythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Placenta increta and endometrial hyperplasia with atypia. A) A representative section from the endometrial biopsy shows hyalinized and infarcted chorionic villi with dystrophic
calciﬁcations. B) The hysterectomy specimen shows extensive involvement of the myometrium by similar hyalinized tissue consistent with placenta increta. C) A portion of the hysterectomy
specimen showsmyometrial blood vessels with thickenedmuscularwalls and inﬁltrationwith hyalinizedmaterial consistent with placenta increta. D) A portion of the hysterectomy specimen
in proximity to the increta shows hyperplastic endometrial glands and focal atypia.
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hyalinized and infarcted chorionic villi with dystrophic calciﬁcations
and extensive myometrial involvement of hyalinized tissue with areas
of focal hemorrhage. These ﬁndings were consistent with placenta
increta (Fig. 1A–C). There was also a focus of endometrial hyperplasia
with atypia in proximity to the increta (Fig. 1D). Both ovaries and
fallopian tubes were normal and pelvic washings were negative for
malignancy.
2. Discussion
Lynch syndrome is an autosomal dominant, familial cancer risk
syndrome, characterized by a germline mutation in DNA mismatch
repair genes: MLH1, MSH2, MSH6, PMS1, and PMS2 (Crispens, 2012;
Lachiewicz et al., 2014). The risk of endometrial cancer, a sentinel cancer
for many women diagnosed with Lynch syndrome, is equivalent to or
greater than the risk of colorectal cancer (Crispens, 2012). Since Lynch
syndrome is associated with hereditary endometrial and ovarian cancers,
gynecologic oncologists play a critical role in performing screening and
risk-reducing prophylactic procedures. Consensus guidelines recommend
that women with known or suspected Lynch syndrome undergo annual
endometrial sampling, starting at ages 30–35 orwhen there is any change
in bleeding patterns (Committee on Practice B-G, Society of Gynecologic
O, 2014; Burt et al., 2013). Routine pelvic ultrasound and CA125 for ovar-
ian cancer surveillance are not endorsed by the National Comprehensive
Cancer Network (NCCN) guidelines for the management of Lynch syn-
drome (Burt et al., 2013).
Prophylactic hysterectomy and BSO is an option for reducing the
risks of both endometrial and ovarian cancers inwomenwhohave com-
pleted childbearing or in the earlymid-40s (themean age of endometri-
al (ages 47–49) and ovarian (ages 42–49) cancers is younger than the
general population) (Committee on Practice B-G, Society of Gynecologic
O, 2014). Preoperative endometrial sampling and intraoperative evalu-
ation of the uterine specimen are warranted since occult preinvasive
lesions and endometrial, ovarian, and fallopian tube cancers have been
detected at the time of prophylactic hysterectomy (Lachiewicz et al.,2014; Karamurzin et al., 2013). To our knowledge, theﬁnding of placen-
ta increta at prophylactic hysterectomy for Lynch syndrome has not
been reported. This unexpected ﬁnding, in addition to the focal endo-
metrial hyperplasia, likely contributed to the patient's postpartum and
intraoperative bleeding. Interestingly, an antenatal diagnosis of abnor-
mal placentationwas notmade despite serial imaging and the diagnosis
of hyperplasia was not made on preoperative curettage. These factors
point to the importance of thorough pathological evaluation of the
ﬁnal specimens. The disrupted interface between the normal endome-
trium and myometrium could be related to Lynch syndrome, however,
we did not ﬁnd any literature to support this intriguing possibility.
Although the precise explanation for the ﬁnding of placenta increta is
not known, in this case risk factors included advanced maternal age
and postpartum D&C for retained products (Publications Committee
SfM-FM and Belfort, 2010).
For MSH6 mutation carriers, the cumulative risk by age 70 of endo-
metrial cancer is approximately 60% and ovarian cancer is approximate-
ly 24% (Burt et al., 2013; Baglietto et al., 2010; Barrow et al., 2013). This
patient was highly motivated to undergo genetics counseling and test-
ing during her second and ﬁnal planned pregnancy, based on her
knowledge of her strong family history of Lynch-associated gynecolog-
ical cancers in multiple female family members in their 40s and 50s.
Once her test results returned as positive for a deleterious MSH6muta-
tion, she expressed a strong desire for risk-reducing surgery as soon as
possible after delivery. The patient underwent extensive counseling
about the risks, beneﬁts, and alternatives of prophylactic surgery in
the postpartum period. A shared decision was made to allow the uterus
to involute and the patient to breastfeed for at least 3 months postpar-
tum without discomfort from surgery.
As awareness about hereditary gynecologic cancer risks increases and
genetics testing becomes increasingly routine, it is likely that prophylactic
gynecologic surgeries will increase. The primary goal of prophylactic sur-
gery is to prevent the development of cancer, while minimizing risks of
complications andnegative effects on quality of life. Counseling should in-
clude desires for future fertility, the medical management of menopause,
and the timing of prophylactic surgery after completion of childbearing.
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pathology should also be stressed.
There is limited information in the literature about the decision-
making process for prophylactic surgery women diagnosed with Lynch
syndrome andwhat exists is qualitative (Etchegary et al., 2015). Guielines
that recommend prophylactic surgery do not specify precise timing after
completion of child-bearing (Committee on Practice B-G, Society of Gyne-
cologic O, 2014). Here, we illustrate the importance of weighing the
patient's desires and concerns about her future risk of developing cancer
and the immediate risks of unexpected ﬁndings and complications from
surgery performed in the postpartum period. Hysterectomy proximate
to delivery poses a higher risk of perioperative complications. The physi-
ologic changes associatedwithpregnancy contribute to the risk of compli-
cations from decreased visibility due to the large size of the uterus,
increased risk of hemorrhage from the large blood vessels and blood vol-
ume supplying the gravid uterus, and other factors related to cardiac out-
put and coagulation (Cunninghamet al., 2013). After the uterus involutes,
minimally invasive options for hysterectomy (vaginal or laparoscopic),
which are associated with better outcomes and fewer complications
(Nieboer et al., 2009; ACOGCommittee Opinion, 2009), become available.
Tomaximize outcomes,we recommended aminimally invasive approach
to be performed after 6 weeks post delivery. Although hysterectomywas
performed 15weeks postpartum in this case, the ﬁnding of an occult pla-
centa increta demonstrates the potential risks of peripartum pathology
and complications beyond 6 weeks.
3. Conclusion
Timing of prophylactic procedures in the postpartum period should
be included in the shared decision making process for the management
of Lynch syndrome and other hereditary cancers. It is important to
assure extensive work up and counseling regarding symptoms and risks
of detecting incidental ﬁndings that include peripartum pathologies and
occult cancer.
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